dc.contributor.author |
Andrés Benito, Pol |
dc.contributor.author |
Domínguez, Raúl |
dc.contributor.author |
Colomina Soler, M. J. (María José) |
dc.contributor.author |
Llorens Torres, Franc |
dc.contributor.author |
Povedano, Mònica |
dc.contributor.author |
Ferrer, Isidro (Ferrer Abizanda) |
dc.date |
2019-09-12T15:13:26Z |
dc.date |
2019-09-12T15:13:26Z |
dc.date |
2018-09-13 |
dc.date |
2019-09-12T15:13:27Z |
dc.identifier.citation |
1945-4589 |
dc.identifier.citation |
683301 |
dc.identifier.uri |
http://hdl.handle.net/2445/139899 |
dc.format |
16 p. |
dc.format |
application/pdf |
dc.language.iso |
eng |
dc.publisher |
Impact Journals |
dc.relation |
Reproducció del document publicat a: https://doi.org/10.18632/aging.101551 |
dc.relation |
Aging, 2018, vol. 10, num. 9, p. 2367-2382 |
dc.relation |
https://doi.org/10.18632/aging.101551 |
dc.rights |
cc-by (c) Andrés Benito, Pol et al., 2018 |
dc.rights |
info:eu-repo/semantics/openAccess |
dc.rights |
http://creativecommons.org/licenses/by/3.0/es |
dc.subject |
Esclerosi lateral amiotròfica |
dc.subject |
Líquid cefalorraquidi |
dc.subject |
Medul·la espinal |
dc.subject |
Amyotrophic lateral sclerosis |
dc.subject |
Cerebrospinal fluid |
dc.subject |
Spinal cord |
dc.title |
YKL40 in sporadic amyotrophic lateral sclerosis: cerebrospinal fluid levels as a prognosis marker of disease progression |
dc.type |
info:eu-repo/semantics/article |
dc.type |
info:eu-repo/semantics/publishedVersion |
dc.description.abstract |
Abstract Amyotrophic lateral sclerosis (ALS) has variable clinical course and fatal outcome. Since inflammation plays a role in the pathogenesis of ALS, chitinase-3-like protein 1 or YKL40 has been assessed as putative biomarker of disease progression. YKL40 mRNA levels are increased in anterior horn of the spinal cord (P=0.004) in sporadic ALS (sALS) cases when compared with age-matched controls. These correlate with increased mRNA expression of microglial markers AIF1 and CD68 in the spinal cord in sALS (P=0.044 and P=0.000, respectively). YKL40 mRNA and protein expression had a tendency to increase in post-mortem frontal cortex area 8 (P=0.06 and P=0.08, respectively). Yet YKL40 immunoreactivity is restricted to a subpopulation of astrocytes in these regions. YKL40 protein levels, as revealed by enzyme-linked immunosorbent assay (ELISA), are significantly increased in the CSF in sALS (n=86) compared with age-matched controls (n=21) (P=0.045). Higher levels are found in patients with fast progression when compared with patients with slow and normal progression (P=0.008 and P=0.004, respectively), and correlates with ALS-FRS-R slope (P=0.000). Additionally, increased protein levels of neurofilament light chain (NF-L) are also found in sALS (P=0.000); highest values are found in patients with fast progression when compared with cases with slow and normal progression (P=0.005 and P=0.000, respectively), and also correlate with ALS-FRS-R slope (P=0.000). Pearson's correlation test linked positively the increased levels of YKL40 with increased NF-L levels (P=0.013). These data point to YKL40 and NF-L protein levels in the CSF as a good biomarker combination of disease progression in sALS. |